Summit Therapeutics SMMT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's total equity?
- Summit Therapeutics (SMMT) reported total equity of $545.93M in Q1 2026.
- How has Summit Therapeutics's total equity changed year-over-year?
- Summit Therapeutics's total equity increased by 58.5% year-over-year, from $344.33M to $545.93M.
- What is the long-term trend for Summit Therapeutics's total equity?
- Over 5 years (2020 to 2025), Summit Therapeutics's total equity has grown at a 52.7% compound annual growth rate (CAGR), from $79.45M to $658.86M.
- What does total equity mean?
- The net value of the company belonging to shareholders, calculated as total assets minus total liabilities.
- How do you interpret total equity?
- An increase generally indicates capital raises or profitable operations, while a decrease may signal losses or significant share buybacks.
- How does total equity compare across companies?
- Varies widely based on the company's stage of development and capital structure strategy.